Overview
- University of Florida researchers analyzed UF Health records from 2012–2024 and found that people with mild cognitive impairment who took glucosamine had about a 25% higher chance of progressing to Alzheimer or a related dementia.
- The same record analysis showed a roughly 25% higher mortality risk for patients with existing Alzheimer‑like dementia who were recorded as taking glucosamine.
- In two‑week mouse experiments using a dose equivalent to about 2,500 mg per day in humans, glucosamine raised sugar attachments on brain proteins and impaired memory in Alzheimer model mice, and blocking excess glycosylation restored memory performance.
- The authors say glucosamine can cross the blood‑brain barrier and that postmortem Alzheimer brain samples showed unusually high levels of these sugar attachments, but they stress the human findings are associative and vulnerable to confounding.
- Researchers and reporters call for patients who take glucosamine—especially those with cognitive impairment—to discuss it with their doctor and for randomized clinical trials to test causation, dose effects, and which patients may be most at risk.